{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:26:11Z","timestamp":1788225971875,"version":"build-2803163510"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,11,1]]},"DOI":"10.2169\/internalmedicine.7609-21","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T22:12:18Z","timestamp":1667254338000},"page":"3189-3196","source":"Crossref","is-referenced-by-count":3,"title":["Reduced Rate of Disease Flares in Japanese Patients with Systemic Lupus Erythematosus: An Altered Balance between the Use of Glucocorticoids and Immunosuppressants in Recent Decades"],"prefix":"10.2169","volume":"61","author":[{"given":"Chihiro","family":"Imaizumi","sequence":"first","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehisa","family":"Ogura","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Takakura","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaharu","family":"Katagiri","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Takenaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennosuke","family":"Mizushina","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Hirata","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis 1: 12-32, 1955.","DOI":"10.1016\/0021-9681(55)90018-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 21: 55-64, 1991.","DOI":"10.1016\/0049-0172(91)90057-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 119: 700-706, 2006.","DOI":"10.1016\/j.amjmed.2005.11.034"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Mu L, Hao Y, Fan Y, et al. Mortality and prognostic factors in Chinese patients with systemic lupus erythematosus. Lupus 27: 1742-1752, 2018.","DOI":"10.1177\/0961203318789788"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 54: 2550-2557, 2006.","DOI":"10.1002\/art.21955"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Doria A, Briani C. Lupus: improving long-term prognosis. Lupus 17: 166-170, 2008.","DOI":"10.1177\/0961203307087612"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73: 958-967, 2014.","DOI":"10.1136\/annrheumdis-2013-205139"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wang Z, Li M, Wang Y, et al. Long-term mortality and morbidity of patients with systemic lupus erythematosus: a single-center cohort study in China. Lupus 27: 864-869, 2018.","DOI":"10.1177\/0961203317751852"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Alarc\u00f3n GS, Ugarte-Gil MF, Pons-Estel G, et al. Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multicenter US cohort. Lupus 28: 423-426, 2019.","DOI":"10.1177\/0961203319826693"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Petri M, Purvey S, Fang H, et al. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 64: 4021-4028, 2012.","DOI":"10.1002\/art.34672"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 15: 30-48, 2019.","DOI":"10.1038\/s41584-018-0133-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nishi E, Kameda H, Ogawa H, et al. Efficacy of weekly mizoribine pulse therapying refractory lupus nephritis. Mod Rheumatol 23: 87-103, 2013.","DOI":"10.3109\/s10165-012-0645-6"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725, 1997.","DOI":"10.1002\/art.1780400928"},{"key":"14","unstructured":"14. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29: 288-291, 2002."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 8: 937-944, 1991.","DOI":"10.1002\/art.1780340802"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ugarte-Gil MF, Acevedo-V\u00e1squez E, Alarc\u00f3n GS, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis 74: 1019-1023, 2015.","DOI":"10.1136\/annrheumdis-2013-204620"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Bandeira M, Buratti S, Bartoli M, et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 15: 515-520, 2006.","DOI":"10.1191\/0961203306lu2316oa"},{"key":"18","unstructured":"18. Mok CC, Ho CT, Wong RW, et al. Damage accrual in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 30: 1513-1519, 2003."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63: 3918-3930, 2011.","DOI":"10.1002\/art.30613"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Griffiths B, Emery P, Ryan V, et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford) 49: 723-732, 2010.","DOI":"10.1093\/rheumatology\/kep396"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II\/III study of rituximab (EXPLORER). Lupus 20: 709-716, 2011.","DOI":"10.1177\/0961203310395802"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377: 721-731, 2011.","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"23","unstructured":"23. Parker B, Urowitz MB, Gladman DD, et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 74: 1530-1536, 2015."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 11: R109, 2009.","DOI":"10.1186\/ar2764"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Feldman CH, Marty FM, Winkelmayer WC, et al. Comparative rates of serious infections among patients with systemic lupus erythematosus receiving immunosuppressive medications. Arthritis Rheumatol 69: 387-397, 2017.","DOI":"10.1002\/art.39849"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mok CC, Tse SM, Chan KL, et al. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus 27: 722-727, 2018.","DOI":"10.1177\/0961203317739129"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Hsu CY, Lin YS, Cheng TT, et al. Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. Rheumatology 57: 1743-1751, 2018.","DOI":"10.1093\/rheumatology\/key167"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/21\/61_7609-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T03:24:40Z","timestamp":1667618680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/21\/61_7609-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":27,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7609-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"article-number":"7609-21"}}